EGFR and non-small cell lung carcinoma: Upfront next-generation sequencing (NGS) for patients with metastatic NSCLC is considered a cost-saving measure in the United States, whereas exclusionary testing for EGFR is considered the most cost-effective method in East Asia, including Taiwan [8,9,10].